Literature DB >> 30079133

Associations between nonalcoholic fatty liver disease and ischemic stroke.

Stelina Alkagiet1, Achilleas Papagiannis1, Konstantinos Tziomalos2.   

Abstract

Nonalcoholic fatty liver disease (NAFLD) is the commonest chronic liver disease and affects a considerable proportion of the general population. NAFLD is independently associated with increased risk for cardiovascular events, particularly coronary heart disease. Importantly, even though NAFLD is more prevalent in patients with major cardiovascular risk factors (e.g., type 2 diabetes mellitus, obesity and hypertension), the association between NAFLD and cardiovascular disease appears to be independent of these risk factors. However, NAFLD also appears to increase the risk for ischemic stroke, a leading cause of mortality and long-term disability worldwide. It also appears that nonalcoholic steatohepatitis is more strongly related to the risk of ischemic stroke than isolated hepatic steatosis. Moreover, emerging data suggest that patients with NAFLD experience more severe ischemic stroke and have more unfavorable prognosis after an acute ischemic stroke in terms of functional dependency and short- and long-term mortality. These associations have major public health implications, since ischemic stroke is the second leading cause of death worldwide and an important cause of long-term disability. The aim of the present review is to summarize the current knowledge regarding the relationship between NAFLD and ischemic stroke incidence, severity and outcome. Given these associations, it might be useful to evaluate patients with acute ischemic stroke for the presence of NAFLD and to manage those with NAFLD more aggressively.

Entities:  

Keywords:  Functional dependency; Incidence; Ischemic stroke; Nonalcoholic fatty liver disease; Outcome; Risk; Severity

Year:  2018        PMID: 30079133      PMCID: PMC6068844          DOI: 10.4254/wjh.v10.i7.474

Source DB:  PubMed          Journal:  World J Hepatol


Core tip: Accumulating data suggest that nonalcoholic fatty liver disease (NAFLD) is independently associated with increased risk for ischemic stroke, a leading cause of mortality and long-term disability worldwide. Moreover, emerging evidence shows that patients with NAFLD experience more severe ischemic stroke and have more unfavorable prognosis after an acute ischemic stroke in terms of functional dependency and short- and long-term mortality.

INTRODUCTION

Nonalcoholic fatty liver disease (NAFLD) is the most frequent chronic liver disease, affects approximately 25% of the general population and is the leading cause of abnormal liver function tests[1,2]. Moreover, the prevalence of NAFLD is even higher in elderly subjects and in patients with type 2 diabetes mellitus (T2DM), obesity, hypertension and/or metabolic syndrome[2,3]. Nonalcoholic steatohepatitis (NASH), a more advanced form of NAFLD, is present in up to 10% of adults[4]. NAFLD can progress to cirrhosis, hepatocellular cancer or liver failure, and is a major cause of liver transplantation[3,5]. Several studies showed that NAFLD is a risk factor for cardiovascular disease (CVD)[6,7]. Importantly, even though NAFLD is more prevalent in patients with major cardiovascular risk factors (e.g., T2DM, obesity and hypertension), the association between NAFLD and CVD appears to be independent of these risk factors (Figure 1)[6,7].
Figure 1

Mechanisms underpinning the association between nonalcoholic fatty liver disease and ischemic stroke (broken line suggests the independent association between nonalcoholic fatty liver disease and ischemic stroke).

Mechanisms underpinning the association between nonalcoholic fatty liver disease and ischemic stroke (broken line suggests the independent association between nonalcoholic fatty liver disease and ischemic stroke). In this context, accumulating data suggest that NAFLD is also associated with increased incidence of ischemic stroke. Moreover, emerging evidence suggests that NAFLD might also be related with more severe stroke and with worse outcome of patients with acute ischemic stroke. These associations have major public health implications, since ischemic stroke is the second leading cause of death worldwide and an important cause of long-term disability[8,9]. The aim of the present review is to summarize the current knowledge regarding the relationship between NAFLD and ischemic stroke incidence, severity and outcome.

NAFLD AND INCIDENCE OF ISCHEMIC STROKE

Several studies reported that elevated aminotransferase and g-glutamyltransferase (gGT) levels, which are mostly due to NAFLD, are associated with increased incidence of ischemic stroke (Table 1). In a small case-control study in 103 patients with acute ischemic stroke and 200 controls, alanine or aspartate aminotransferase levels were independently associated with increased odds ratio for ischemic stroke[10]. In a larger prospective study in 6997 men without established CVD or T2DM, gGT levels, a more specific marker of NAFLD, was independently associated with higher risk of ischemic stroke, even in subjects at low- or moderate cardiovascular risk[11]. In EUROSTROKE, a nested-case control study performed in 3 European countries (Finland, Netherlands and United Kingdom), the association between gGT levels and ischemic stroke risk appeared to be stronger in patients without T2DM[12]. Importantly, gGT appears to play a role in atherogenesis[13]. Indeed, gGT has been isolated from atheromatic plaques, macrophages and foam cells[14] and appears to contribute to atherosclerosis by inducing oxidative stress[15]. It was shown than gGT promotes oxidization of low-density lipoprotein and that it plays a crucial role in the catabolism of glutathione and the release of reactive oxygen species[16,17]. In a recent cross-sectional study, NAFLD diagnosed with ultrasonography was associated with increased prevalence of lacunar infarcts in non-obese subjects but not in obese patients[18]. In contrast, in another recent case-cohort study in 572 patients with incident ischemic stroke and 1017 controls, NAFLD defined as fatty liver index > 60 was associated with lower risk in men but there was no association in women[19]. In a meta-analysis of 9 case-control and cohort studies, NAFLD was independently associated with 2.3 times higher risk for ischemic stroke (95%CI: 1.84-2.93)[20]. The strength of this association was comparable in Caucasian and Asian patients[20]. Importantly, this association was independent of traditional cardiovascular risk factors, including dyslipidemia, obesity and T2DM[20].
Table 1

Major studies that evaluated the association between nonalcoholic fatty liver disease and ischemic stroke

Ref.DesignMean age (yr)Follow-upOutcome
[7]Prospective observational study in 1637 healthy Japanese men/women47.82 yrHigher incidence of CVD including stroke in patients with NAFLD compared with controls
[22]Prospective study in 242 patients admitted with acute stroke662 yrIncreased risk of acute stroke, more severe stroke and worse outcome in patients with NAFLD
[11]Prospective study in 6997 men with no history of CVD or diabetes mellitus40-5924 yrAssociation between gGT and higher incidence of fatal, major stroke events and total CVD mortality
[10]Cross sectional study in adults with suspected acute stroke20-27Not applicableElevated ALP and ALT levels independently associated with higher risk of acute stroke
[12]Case-control study using data from 3 European cohort studies in 13177 subjects40-603-8 yrElevated gGT levels associated with higher risk of stroke
[21]Case-control study in 295 patients with acute stroke and 1942 healthy subjects60Not applicableLiver fibrosis was associated with higher incidence of ischemic stroke
[20]Meta analysis of 9 studies that examined relation of NAFLD and strokeNot reportedNot applicableHigher risk of ischemic stroke and hemorrhagic stroke in patients with NAFLD
[23]Retrospective study in 306 patients with confirmed brainstem infractions65Not applicableHigher incidence of brainstem infracts in patients with NAFLD
[24]Study in 415 patients admitted with acute ischemic stroke78.8Duration of hospitalizationNAFLD was not associated with stroke severity at admission or outcome during hospitalization
[19]Case-cohort study in 572 patients with stroke and 1017 controls> 455.8 yrFatty liver index associated with increased risk for ischemic stroke in women and with lower risk in women
[20]Cross-sectional study in 1277 subjects who underwent brain magnetic resonance imaging and abdominal ultrasound during check-up> 40 yrNot applicableNAFLD diagnosed with ultrasonography was associated with increased prevalence of lacunar infarcts in non-obese subjects but not in obese patients

CVD: Cardiovascular disease; gGT: G-glutamyltransferase; ALP: Alkaline phosphatase; ALT; Alanine aminotransferase; NAFLD: Nonalcoholic fatty liver disease.

Major studies that evaluated the association between nonalcoholic fatty liver disease and ischemic stroke CVD: Cardiovascular disease; gGT: G-glutamyltransferase; ALP: Alkaline phosphatase; ALT; Alanine aminotransferase; NAFLD: Nonalcoholic fatty liver disease. It appears that NASH is more strongly related to the risk of ischemic stroke than isolated hepatic steatosis. Indeed, in a case-control study in 295 patients with acute ischemic stroke and 1942 subjects who underwent a health check-up, the degree of liver fibrosis, evaluated with transient elastography, was independently associated with increased stroke risk[21]. In contrast, isolated steatosis was not related with the risk of stroke[21].

NAFLD AND SEVERITY AND OUTCOME OF ISCHEMIC STROKE

There are very few data regarding the impact of NAFLD on the severity and outcome of ischemic stroke (Table 1). In an early prospective study in 200 patients admitted with acute ischemic stroke, NAFLD (defined as elevated aminotransferase levels in the absence of other causes) was present in 42.5% of patients[22]. Patients with NAFLD had more severe stroke at admission and worse functional outcome at discharge[22]. However, patients with NAFLD were more obese, had higher prevalence of T2DM and had higher low-density lip–oprotein cholesterol and triglyceride levels than patients without NAFLD; these differences were not adjusted for in the comparisons of stroke severity and outcome between the 2 groups[22]. In a more recent retrospective study in 306 patients with brainstem infarction, a similar prevalence of NAFLD (defined as elevated aminotransferase levels in the absence of other causes) was reported (42.5%)[23]. Patients with NAFLD had more severe stroke at admission and higher risk for neurological deterioration during hospitalization, independently of other risk factors[23]. In contrast, in a prospective study in 415 consecutive patients with acute ischemic stroke, stroke severity at admission, functional outcome at discharge and in-hospital mortality did not differ between patients with NAFLD (defined as elevated aminotransferase levels without another apparent cause) and those without NAFLD after adjustment for other cardiovascular risk factors[24]. However, only 32 patients (7.7% of the study population) had NAFLD[24]. Therefore, this study might have lacked the power to identify an association between NAFLD and stroke severity and outcome[24].

CONCLUSION

Accumulating data suggest that NAFLD is independently associated with increased risk for ischemic stroke. Moreover, it appears that patients with NAFLD experience more severe stroke and have more adverse functional outcome than patients without NAFLD. Therefore, it might be useful to evaluate patients with acute ischemic stroke for the presence of NAFLD and to manage those with NAFLD more aggressively. It remains to be established whether management of NAFLD will also reduce the risk and improve the outcome of ischemic stroke.
  23 in total

1.  Non-obese fatty liver disease is associated with lacunar infarct.

Authors:  Min-Sun Kwak; Kyung Won Kim; Hyobin Seo; Goh-Eun Chung; Jeong Yoon Yim; Donghee Kim
Journal:  Liver Int       Date:  2018-01-08       Impact factor: 5.828

2.  Non-alcoholic fatty liver disease is associated with stroke severity and progression of brainstem infarctions.

Authors:  H Li; B Hu; L Wei; L Zhou; L Zhang; Y Lin; B Qin; Y Dai; Z Lu
Journal:  Eur J Neurol       Date:  2018-01-18       Impact factor: 6.089

3.  The global burden of disease study: implications for neurology.

Authors:  M Menken; T L Munsat; J F Toole
Journal:  Arch Neurol       Date:  2000-03

4.  Glutathione metabolism by gamma-glutamyltranspeptidase leads to lipid peroxidation: characterization of the system and relevance to hepatocarcinogenesis.

Authors:  A A Stark; E Zeiger; D A Pagano
Journal:  Carcinogenesis       Date:  1993-02       Impact factor: 4.944

5.  Gamma-glutamyltransferase activity in human atherosclerotic plaques--biochemical similarities with the circulating enzyme.

Authors:  Maria Franzini; Alessandro Corti; Barbara Martinelli; Antonella Del Corso; Michele Emdin; Giuliano F Parenti; Mattia Glauber; Alfonso Pompella; Aldo Paolicchi
Journal:  Atherosclerosis       Date:  2008-04-11       Impact factor: 5.162

6.  The value of gamma-glutamyltransferase in cardiovascular risk prediction in men without diagnosed cardiovascular disease or diabetes.

Authors:  S G Wannamethee; L Lennon; A G Shaper
Journal:  Atherosclerosis       Date:  2008-03-10       Impact factor: 5.162

7.  High Prevalence of Liver Fibrosis Among European Adults With Unknown Liver Disease: A Population-Based Study.

Authors:  Llorenç Caballería; Guillem Pera; Ingrid Arteaga; Lluís Rodríguez; Alba Alumà; Rosa Ma Morillas; Napoleón de la Ossa; Alba Díaz; Carmen Expósito; Dolores Miranda; Carmen Sánchez; Rosa Ma Prats; Marta Urquizu; Angels Salgado; Magda Alemany; Alba Martinez; Irfan Majeed; Núria Fabrellas; Isabel Graupera; Ramón Planas; Isabel Ojanguren; Miquel Serra; Pere Torán; Juan Caballería; Pere Ginès
Journal:  Clin Gastroenterol Hepatol       Date:  2018-02-13       Impact factor: 11.382

8.  The natural history of nonalcoholic fatty liver disease with advanced fibrosis or cirrhosis: an international collaborative study.

Authors:  Neeraj Bhala; Paul Angulo; David van der Poorten; Eric Lee; Jason M Hui; Giorgio Saracco; Leon A Adams; Phunchai Charatcharoenwitthaya; Joanne H Topping; Elisabetta Bugianesi; Christopher P Day; Jacob George
Journal:  Hepatology       Date:  2011-08-09       Impact factor: 17.425

9.  Presence and severity of non-alcoholic fatty liver disease in a large prospective primary care cohort.

Authors:  Matthew J Armstrong; Diarmaid D Houlihan; Louise Bentham; Jean C Shaw; Robert Cramb; Simon Olliff; Paramjit S Gill; James M Neuberger; Richard J Lilford; Philip N Newsome
Journal:  J Hepatol       Date:  2011-05-18       Impact factor: 25.083

10.  Non-alcoholic fatty liver disease, liver biomarkers and stroke risk: The Reasons for Geographic and Racial Differences in Stroke cohort.

Authors:  Kristine S Alexander; Neil A Zakai; Steven D Lidofsky; Peter W Callas; Suzanne E Judd; Russell P Tracy; Mary Cushman
Journal:  PLoS One       Date:  2018-03-12       Impact factor: 3.240

View more
  9 in total

Review 1.  Optimizing patients with non-alcoholic fatty liver disease pre-transplant.

Authors:  Amine Benmassaoud; Marc Deschenes; Tianyan Chen; Peter Ghali; Giada Sebastiani
Journal:  Can Liver J       Date:  2020-08-20

2.  Fatty Liver Index Independently Predicts All-Cause Mortality in Patients With Antineutrophil Cytoplasmic Antibody-Associated Vasculitis but No Substantial Liver Disease.

Authors:  Pil Gyu Park; Jung Yoon Pyo; Sung Soo Ahn; Hyun Joon Choi; Jason Jungsik Song; Yong-Beom Park; Ji Hye Huh; Sang-Won Lee
Journal:  Front Cardiovasc Med       Date:  2022-06-23

3.  Presence of diabetic retinopathy is lower in type 2 diabetic patients with non-alcoholic fatty liver disease.

Authors:  Meng Zhang; Li Li; Jing Chen; Bei Li; Yutao Zhan; Chuan Zhang
Journal:  Medicine (Baltimore)       Date:  2019-05       Impact factor: 1.817

Review 4.  Pathophysiological Molecular Mechanisms of Obesity: A Link between MAFLD and NASH with Cardiovascular Diseases.

Authors:  Jorge Gutiérrez-Cuevas; Arturo Santos; Juan Armendariz-Borunda
Journal:  Int J Mol Sci       Date:  2021-10-27       Impact factor: 5.923

5.  Association Between Non-alcoholic Fatty Liver Disease and Risk of Stroke: A Systematic Review and Meta-Analysis.

Authors:  Meng Wang; Ben-Gang Zhou; Yi Zhang; Xi-Fang Ren; Ling Li; Bo Li; Yao-Wei Ai
Journal:  Front Cardiovasc Med       Date:  2022-03-08

6.  Non-alcoholic fatty liver disease (NAFLD) and the cardiovascular disease (CVD) risk categories in primary care: is there an association?

Authors:  Hayatul Najaa Miptah; Anis Safura Ramli; Mariam Mohamad; Hilwati Hashim; Zahirah Tharek
Journal:  BMC Fam Pract       Date:  2020-11-20       Impact factor: 2.497

7.  Association of non-alcoholic fatty liver disease with diabetic retinopathy in type 2 diabetic patients: A meta-analysis of observational studies.

Authors:  Dandan Song; Chengqian Li; Zhongchao Wang; Yuhang Zhao; Baoming Shen; Wenjuan Zhao
Journal:  J Diabetes Investig       Date:  2021-02-01       Impact factor: 4.232

8.  Non-alcoholic fatty liver disease frequency and associated factors at admission of acute stroke.

Authors:  Takahisa Mori; Kazuhiro Yoshioka; Yuhei Tanno
Journal:  Hepatol Int       Date:  2021-09-15       Impact factor: 6.047

9.  Association between non-alcoholic fatty liver and acute cerebral infarction: a protocol of systematic review and meta-analysis.

Authors:  Ya-Juan Zhang; Wen-Juan Liu
Journal:  Medicine (Baltimore)       Date:  2020-06-12       Impact factor: 1.817

  9 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.